Pathology

Dawn E. Quelle, PhD

Portrait

Associate Professor of Pharmacology
Associate Professor of Pathology

Contact Information

Primary Office: 2-570 Bowen Science Building
Iowa City, IA 52242
Primary Office Phone: 319-353-5749

Lab: 2-551 Bowen Science Building
Iowa City, IA 52242
Phone: 319-335-7663

Email: dawn-quelle@uiowa.edu

Education

BS, Biochemistry, University of Maine, Orono
PhD, Molecular & Cell Biology, The Pennsylvania State University, University Park

Fellowship, The Pennsylvania State University
Postdoctoral Fellow, Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN
Associate, Howard Hughes Medical Institute at St. Jude Children's Research Hospital, Memphis, TN

Education/Training Program Affiliations

Biosciences Graduate Program
Interdisciplinary Graduate Program in Molecular and Cellular Biology
Interdisciplinary Graduate Program in Translational Biomedicine
Medical Scientist Training Program

Research Summary

Molecular Mechanisms of Tumorigenesis and Cell Cycle Control My research is centered on understanding molecular mechanisms that control cell proliferation and checkpoint responses, and how those processes are disrupted during tumorigenesis. A principal focus of the lab is the ARF tumor suppressor, which is encoded by a gene (INK4a/ARF) that is inactivated in 40-50% of all human cancers. ARF inhibits tumorigenesis through p53-dependent and p53-independent signaling pathways that are complex and only partially defined. That is because ARF functions through numerous binding partners (at least 30) to promote apoptosis or senescence, inhibit migration/invasion and metastasis, sustain cell stress checkpoints and maintain chromosomal stability. Our goal is to define the critical regulators of ARF signaling and determine their significance to tumor suppression using molecular approaches and in vivo models of cancer. In so doing, we will advance our fundamental understanding of ARF-mediated tumor suppression and also identify novel regulators of growth (both positive and negative) whose characterization will likely contribute to new paradigms of carcinogenesis. Such knowledge is essential to providing new markers for tumor detection and developing useful, targeted anticancer strategies.

All Publications

Huang J, Stewart A, Maity B, Hagen J, Hagen R, Quelle D, Brenner C, Fisher R.  RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis.  Oncogene.  2013 September 2. 
[PubMed]

Muniz V, Askeland R, Zhang X, Reed S, Tompkins V, Hagen J, Button A, Smith B, Zamba G, Weydert J, Mezhir J, Quelle D.  RABL6A promotes oxaliplatin resistance in tumor cells and is a new marker of survival for resected pancreatic ductal adenocarcinoma patients.  Genes & Cancer.  2013. 

Zhang X, Hagen J, Muniz V, Smith T, Coombs G, Eischen C, Mackie D, Roman D, Van Rheeden R, Darbro B, Quelle D.  RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.  PLoS ONE.  2013. 

Anderson M, D'Allesandro D, Quelle D, Axelson R, Geist L, Black D.  Recognizing Diverse Forms of Scholarship in the Modern Medical College.  2013. 

Reed S, Tompkins V, Hagen J, Cryderman D, Wallrath L, Quelle D.  Mechanisms of p53 activation by NIAM, Nuclear Interactor of ARF and MDM2.  AACR.  2012. 

Muniz V, Zhang X, Reed S, Tompkins V, Smith T, Hagen J, Fitzgerald M, Button A, Smith B, Zamba K, Domann F, Mezhir J, Weydert J, Askeland R, Quelle D.  Parf-1A (Partner of ARF isoform 1A) promotes oxaliplatin resistance and is a new prognostic marker of survival in pancreatic ductal adenocarcinoma.  AACR.  2012. 

Muniz V, Barnes J, Paliwal S, Zhang X, Tang X, Chen S, Zamba K, Cullen J, Meyerholz D, Meyers S, Davis J, Grossman S, Henry M, Quelle D.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis..  Molecular cancer research : MCR.  2011 July. 9(7):867-77.
[PubMed]

Stivers J, Fernandes Hagen J, Quelle D.  Studies of a novel breast cancer inhibitor, NIAM.  Tumor Suppressors Section.  2011. 

Muniz V, Barnes J, Paliwal S, Zhang X, Tang X, Chen S, Zamba K, Cullen J, Meyerholz D, Meyers S, Davis J, Grossman S, Henry M, Quelle D.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.  Biology of Cancer: Microenvironment, Metastasis & Therapies.  2011. 

Francis S, Tompkins V, Hagen J, Stiver J, Quelle D.  Role of NIAM (Nuclear Interactor of ARF and Mdm2) in p53 Signaling and DNA Damage Checkpoints.  Health Sciences Research Week Poster Session.  2010. 

Francis S, Tompkins V, Hagen J, Stiver J, Quelle D.  Role of NIAM in p53 Signaling and DNA Damage Checkpoints.  Heart Science Poster Session.  2010. 

di Tommaso A, Hagen J, Tompkins V, Muniz V, Dudakovic A, Kitzis A, Ladeveze V, Quelle D.  Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities..  Experimental cell research.  2009 April. 315(7):1326-35.
[PubMed]

Tompkins V, Han S, Qi C, Morse H, Quelle D, Janz S.  Potential role for NIAM/Tbrg1 in B cell neoplasia.  AACR.  2009. 

Tompkins V, Han S, Qi C, Morse H, Quelle D, Janz S.  Potential role for NIAM/Tbrg1 in B cell neoplasia.  AACR.  2009. 

Tompkins V, Han S, Qi C, Morse H, Quelle D, Janz S.  Potential role for NIAM/Tbrg1 in B cell neoplasia.  Research Week.  2009. 

Hagen J, Tompkins V, Dudakovic A, Weydert J, Quelle D.  Generation and characterization of monoclonal antibodies to NIAM: a nuclear interactor of ARF and Mdm2..  Hybridoma (Larchmt).  2008 June. 27(3):159-66.
[PubMed]

Muniz V, diTommaso A, Hagen J, Tompkins V, Kitzis A, Ladeveze V, Quelle D.  Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities.  Cancer Genetics and Tumor Suppressor Genes.  2008. 

Groskreutz D, Monick M, Yarovinsky T, Powers L, Quelle D, Varga S, Look D, Hunninghake G.  Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells..  Journal of immunology (Baltimore, Md. : 1950).  2007 September. 179(5):2741-7.
[PubMed]

Smith T, Tompkins V, Hagen J, Fitsgerald M, Domann R, Lushnikova T, Eischen C, Quelle D.  Identification of novel regulators of growth and ARF tumor suppressor signaling.  The Association of Biochemistry and Molecular Biology.  2007. 

Tompkins V, Hagen J, Frazier A, Lushnikova T, Fitzgerald M, di Tommaso A, Ladeveze V, Domann F, Eischen C, Quelle D.  A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability..  The Journal of biological chemistry.  2007 January. 282(2):1322-33.
[PubMed]

Tompkins V, Hagen J, Zediak V, Quelle D.  Identification of novel ARF binding proteins by two-hybrid screening..  Cell cycle (Georgetown, Tex.).  2006 March. 5(6):641-6.
[PubMed]

Miller S, Rangwala F, Williams J, Ackerman P, Kong S, Jegga A, Kaiser S, Aronow B, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle D, Watson M, Perry A, Gutmann D, Ratner N.  Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues..  Cancer research.  2006 March. 66(5):2584-91.
[PubMed]

Tompkins V, Hagen J, Frazier A, Boyd J, di Tommaso A, Ladeveze V, Quelle D.  NIAM, a Nuclear Interactor of ARF and Mdm2 and novel growth inhibitor.  AACR.  2006. 

Datta A, Sen J, Hagen J, Korgaonkar C, Caffrey M, Quelle D, Hughes D, Ackerson T, Costa R, Raychaudhuri P.  ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF..  Molecular and cellular biology.  2005 September. 25(18):8024-36.
[PubMed]

Korgaonkar C, Hagen J, Tompkins V, Frazier A, Allamargot C, Quelle F, Quelle D.  Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function..  Molecular and cellular biology.  2005 February. 25(4):1258-71.
[PubMed]

Frazier A, Sorensen B, Tompkins V, Hagen J, Swihart F, Boyd J, Shea M, Quelle D.  Biophysical characterization of the full-length tumor suppressor protein, p14 ARF.  International Biophysics Congress.  2005. 

Frazier A, Tompkins V, Hagen J, Sorensen B, Shea M, Quelle D.  Biophysical studies of the full-length human ARF tumor suppressor protein.  Annual Mdm2 Meeting.  2005. 

Tompkins V, Hagen J, Frazier A, Swihart F, Boyd J, Raborn T, Quelle D.  Identification of a novel growth suppressor and ARF binding protein, Abp1.  Cellular Senescence and Cell Death.  2005. 

Tompkins V, Hagen J, Luo X, Quelle D.  A novel protein, Parf2, negatively regulates ARF-mediated cell cycle arrest.  Cancer Genetics and Tumor Suppressor Genes.  2004. 

Chandrashekhar K, Hagen J, Tompkins V, Quelle F, Quelle D.  Nucleophosmin (NPM/B23) targets ARF to nucleoli and inhibits its function.  AACR.  2004. 

Chandrashekhar K, Hagen J, Tompkins V, Frazier A, Quelle F, Quelle D.  Nucleophosmin (NPM/B23) targets ARF to nucleoli and inhibits its function.  Cancer Genetics and Tumor Suppressor Genes.  2004. 

Tompkins V, Hagen J, Luo X, Quelle D.  Characterization of a novel ARF-associated protein, Parf2.  Keystone Symposium on the Molecular Targets for Cancer Therapy.  2003. 

Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, Horne M, Quelle D.  Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways..  Molecular cancer research : MCR.  2003 January. 1(3):195-206.
[PubMed]

Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel W, van der Reijden B, Quelle D, Rowley J, Cleveland J, Jansen J, Pandolfi P, Hiebert S.  The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia..  Nature medicine.  2002 July. 8(7):743-50.
[PubMed]

Zhao L, Samuels T, Singamkutti A, Horne M, Quelle D.  Cycling G1 inhibits cell growth and associates with the Mdm2 oncoprotein.  AACR.  2002. 

Korgaonkar C, Zhao L, Modestou M, Quelle D.  ARF function does not require p53 stabilization or Mdm2 relocalization..  Molecular and cellular biology.  2002 January. 22(1):196-206.
[PubMed]

Eapen A, Henry M, Quelle D, Quelle F.  Dna damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2..  Molecular and cellular biology.  2001 September. 21(18):6113-21.
[PubMed]

Modestou M, Puig-Antich V, Korgaonkar C, Eapen A, Quelle D.  The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways..  Cancer research.  2001 April. 61(7):3145-50.
[PubMed]

Korgaonkar C, Zhao L, Modestou M, Quelle D.  Mutational analyses of murine ARF.  Signaling to Cell Growth and Death.  2001. 

Luo X, Quelle D.  Identification and characterization of ARF-associated proteins.  American Association for Cancer Research Annual Meeting.  2000. 

Puig-Antich V, Korgaonkar C, Modestou M, Quelle D.  Growth inhibition by the ARF tumor suppressor does not require p21Cip1.  Gordon Research Conference on Cancer.  1999. 

Korgaonkar C, Puig-Antich V, Quelle D.  Growth inhibition by the ARF tumor suppressor does not require p21Cip1.  The Association of Biochemistry and Molecular Biology.  1999. 

Kamijo T, Zindy F, Roussel M, Quelle D, Downing J, Ashmun R, Grosveld G, Sherr C.  Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF..  Cell.  1997 November. 91(5):649-59.
[PubMed]

Zindy F, Quelle D, Roussel M, Sherr C.  Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging..  Oncogene.  1997 July. 15(2):203-11.
[PubMed]

Quelle D, Cheng M, Ashmun R, Sherr C.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF..  Proceedings of the National Academy of Sciences of the United States of America.  1997 January. 94(2):669-73.
[PubMed]

Quelle D, Zindy F, Ashmun R, Sherr C.  Identification and characterization of p19ARF, another protein derived from the INK4a gene which induces cell cycle arrest.  The Cell Cycle.  1996. 

Schmidt E, Gadd M, Pisc C, Johnston K, Nong Y, Quelle D.  Regulated expression of INK4a-p16 during mammary growth and involution.  The Cell Cycle.  1996. 

Quelle D, Zindy F, Ashmun R, Sherr C.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest..  Cell.  1995 December. 83(6):993-1000.
[PubMed]

Linardopoulos S, Street A, Quelle D, Parry D, Peters G, Sherr C, Balmain A.  Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors..  Cancer research.  1995 November. 55(22):5168-72.
[PubMed]

Quelle D, Ashmun R, Hannon G, Rehberger P, Trono D, Richter K, Walker C, Beach D, Sherr C, Serrano M.  Cloning and characterization of murine p16INK4a and p15INK4b genes..  Oncogene.  1995 August. 11(4):635-45.
[PubMed]

Sherr C, Matsushime H, Kato J, Quelle D, Roussel M.  Control of G1 progression by mammalian D-type cyclins.  1995. 

He T, Jiang N, Zhuang H, Quelle D, Wojchowski D.  The extended box 2 subdomain of erythropoietin receptor is nonessential for Jak2 activation yet critical for efficient mitogenesis in FDC-ER cells..  The Journal of biological chemistry.  1994 July. 269(28):18291-4.
[PubMed]

Matsushime H, Quelle D, Shurtleff S, Shibuya M, Sherr C, Kato J.  D-type cyclin-dependent kinase activity in mammalian cells..  Molecular and cellular biology.  1994 March. 14(3):2066-76.
[PubMed]

Sherr C, Kato J, Quelle D, Matsuoka M, Roussel M.  D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response..  Cold Spring Harbor symposia on quantitative biology.  1994. 59:11-9.
[PubMed]

Quelle D, Matsushime H, Kato J, Roussel M, Sherr C.  Expression of D-type cyclin-dependent kinases in mammalian cells.  The Cell Cycle.  1994. 

Quelle D, Ashmun R, Shurtleff S, Kato J, Bar-Sagi D, Roussel M, Sherr C.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts..  Genes & development.  1993 August. 7(8):1559-71.
[PubMed]

Sherr C, Quelle D, Kato J, Shurtleff S, Roussel M.  D-type cyclins and G1 progression.  1993. 

Quelle D, Ashmun R, Shurtleff S, Kato J, Roussel M, Sherr C.  Overexpression of mouse D-type cyclins accelerates G1-phase progression in rodent fibroblasts.  Meeting on Oncogenes.  1993. 

Quelle D, Lynch K, Burkert-Smith R, Weiss S, Whitford W, Wojchowski D.  Phosphorylatable and epitope-tagged human erythropoietins: utility and purification of native baculovirus-derived forms..  Protein expression and purification.  1992 December. 3(6):461-9.
[PubMed]

Quelle D, Quelle F, Wojchowski D.  Mutations in the WSAWSE and cytosolic domains of the erythropoietin receptor affect signal transduction and ligand binding and internalization..  Molecular and cellular biology.  1992 October. 12(10):4553-61.
[PubMed]

Quelle F, Quelle D, Wojchowski D.  Interleukin 3, granulocyte-macrophage colony-stimulating factor, and transfected erythropoietin receptors mediate tyrosine phosphorylation of a common cytosolic protein (pp100) in FDC-ER cells..  The Journal of biological chemistry.  1992 August. 267(24):17055-60.
[PubMed]

Quelle D, Wojchowski D.  Mutations in the WSAWSE and cytosolic domains of the EPO receptor affect signal transduction, ligand binding, and internalization.  Summer Symposium in Molecular Biology.  1992. 

Quelle D, Quelle F, Wojchowski D.  Structure/function studies of the murine erythoropoietin receptor.  Keystone Symposium in Cytokine Signaling.  1992. 

Quelle D, Wojchowski D.  Localized cytosolic domains of the erythropoietin receptor regulate growth signaling and down-modulate responsiveness to granulocyte-macrophage colony-stimulating factor..  Proceedings of the National Academy of Sciences of the United States of America.  1991 June. 88(11):4801-5.
[PubMed]

Quelle D, Wojchowski D.  Localized cytosolic domains of the EPO receptor affect growth signaling and responsiveness to GM-CSF.  Summer Symposium in Molecular Biology.  1990. 

Quelle D, Wojchowski D.  Pathogens and model systems.  Summer Symposium in Molecular Biology.  1988. 

Hagen J, Reed S, Askeland R, Howe J, O'Dorisio S, Klingelhutz A, Quelle F, Darbro B, Quelle D.  A critical role for RABL6A in Rb inactivation and neuroendocine tumor proliferation. 

Muniz V, Reed S, Stivers J, Hagen J, Shaik A, Naber M, Fitzgerald M, Futscher B, Domann F, Fajardo L, Spitz D, Quelle D.  NIAM acts independent of p53 to sensitize breast cancer cells to doxorubicin and irradiation. 

Reed S, Hagen J, Tompkins V, Wallrath L, Quelle F, Quelle D.  Nuclear Interactor of ARF and Mdm2 acts through multiple pathways to activate p53. 

Hagen J, Zhang X, Muniz V, Kosmacek E, Mackey M, Ianzini F, Assem M, Fuller G, Bogler O, Askeland R, Quelle D.  RABL6A is required for the cytokinesis and survival of human astrocytes and is aberrantly expressed in glioblastoma multiforme. 

Date Last Modified: 06/07/2014 - 21:56:23